VRI Biomedical was a Perth-based listed company in the early 2000s after a $8.8 million raising. It floated on the ASX in 2000.
In 2005 it changed its name to Probiomics, reflecting the name of one of its products, and dual-listed on the London Stock Exchanges Alternative Investments Market (AIM). One of its areas of focus was a flu vaccine.
In 2012 it changed its name to Bioxyne as part of a takeover of Hunter Immunology.